We offer several patient-reported outcome (PRO) measurement solutions that can help document the etiology, progression, patient experience, symptoms and impact of rare diseases.
Mr. Hart will join the team led by Chief Executive Officer Garth “Gus” Gardner, who has been in that role since soon after the VSCP-led recapitalization of the company in August of 2020.Read More
QualityMetric’s own Kimberly Raymond, Andrew Lovley, and Michelle White co-author a new study on the humanistic burden of hereditary transthyretin (hATTR) amyloidosis from the patient’s perspective.Read More
QualityMetric’s Vice President and Senior Scientist, Mark Kosinski, co-authors a study for determining whether the content of the Asthma Control Test (ACT) serves as a valid measure of asthma control.Read More
Our experts provide medical device clients with leading strategic measurement services, qualitative and quantitative research and patient journey studies, PRO outcomes analyses, rare disease research, and PRO regulatory support services.Read More
As pharma, biotech, medical device companies and academic researchers race to discover treatments for COVID-19, they require measurement and outcomes reporting for capturing real-world evidence.Read More
We want to inform you of a recent development that will allow us to enhance the services and support we provide.Read More
Gardner’s appointment comes as the company seeks to build on its position as the preeminent provider of Patient Reported Outcomes (PRO) and Clinical Outcome Assessments (COA) solutions and services to healthcare and life sciences companies.Read More